MetaCap

PMGC (ELAB) vs PRF Technologies (PRFX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

PRF Technologies is the larger company by market cap ($1.7 million vs $1.3 million), about 1.2 times the size. PMGC converts more of its revenue into profit, with a net margin of -1313.0% versus -29541.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELAB-63.69%PRFX-45.79%
+3%-32%-67%
Oct 7, 20261 yearNov 20, 2026
ELAB-62.99%PRFX-45.86%
+3%-31%-66%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELAB versus PRFX key metrics
MetricELABPRFX
Share price$1.14$0.4758
Market cap$1.33M$1.66M
1-day change-10.24%-23.68%
EPS (TTM)$-555.60$-4.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$590.08K$17.00K
Net income (latest FY)$-7.75M$-5.02M
Gross margin31.40%-311.76%
Operating margin—-30129.41%
Net margin-1313.00%-29541.18%
52-week high$1,344.00$7.95
52-week low$1.14$0.46
Distance from 52-week high-99.92%-94.02%
Average volume279.01K228.55K
Shares outstanding1.17M3.50M
Employees326
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PMGC is more profitable, keeping -1313.0 cents of every revenue dollar as net income versus -29541.2 cents for PRF Technologies.

About PMGC

ELAB stock →

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.

Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees

About PRF Technologies

PRFX stock →

PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

ELAB vs PRFX FAQ

Which is bigger, PMGC or PRF Technologies?

PRF Technologies (PRFX) is larger, with a market capitalization of $1.66M compared with $1.33M for PMGC (ELAB).

Are PMGC and PRF Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons